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Abstract
Background: Cell cultures have become an indispensable tool in Alzheimer's disease research for
studying amyloid-β (Aβ) metabolism. It is estimated that up to 35% of cell cultures in current use
are infected with various mycoplasma species. In contrast with common bacterial and fungal
infections, contaminations of cell cultures with mycoplasmas represent a challenging issue in terms
of detectability and prevention. Mycoplasmas are the smallest and simplest self-replicating bacteria
and the consequences of an infection for the host cells are variable, ranging from no apparent effect
to induction of apoptosis.
Findings: Here we present evidence that mycoplasmas from a cell culture contamination are able
to efficiently and rapidly degrade extracellular Aβ. As a result, we observed no accumulation of Aβ
in the conditioned medium of mycoplasma-positive cells stably transfected with the amyloid-β
precursor protein (APP). Importantly, eradication of the mycoplasma contaminant – identified as
M. hyorhinis – by treatments with a quinolone-based antibiotic, restored extracellular Aβ
accumulation in the APP-transfected cells.
Conclusion: These data show that mycoplasmas degrade Aβ and thus may represent a significant
source of variability when comparing extracellular Aβ levels in different cell lines. On the basis of
these results, we recommend assessment of mycoplasma contaminations prior to extracellular Aβ
level measurements in cultured cells.
Findings
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder characterized by the presence of classical
lesions in different brain regions of the neocortex and hip-
pocampus [1]. Among these lesions, the amyloid plaques
formed by the aggregation of amyloid-β (Aβ) peptides are
prominent. The pathogenesis of the disease is complex
and is driven by both environmental and genetic factors.
Although most of the cases are sporadic with an obscure
etiology, some forms of the disease are inherited and sev-
eral genes are implicated in familial Alzheimer's disease
(FAD). The understanding of the molecular basis of the
disease gained significant knowledge with the observation
that mutations in the three genes linked to early-onset
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autosomal dominant FAD, increase the production of a
highly insoluble isoform of Aβ. Together, these observa-
tions support the so-called amyloid hypothesis in the
pathogenesis of Alzheimer's disease [2,3]. Sequential
endoproteolysis of the amyloid-β precursor protein (APP)
by the aspartic protease β-secretase/BACE1 and by the γ-
secretase proteolytic complex leads to the production of
Aβ (see Figure 1A). In an alternative non-amyloidogenic
pathway, APP is endoproteolyzed within the Aβ region by
α-secretase to produce the secreted sAPPα fragment (Fig-
ure 1A) [4,5].
Numerous primary and immortalized cell lines have been
used to analyze APP processing and Aβ production in in
vitro cultures. These cell culture systems have proven to be
indispensable for the identification of pharmacological
and genetic modifiers of APP metabolism prior to in vivo
studies [6-8]. It is estimated that 15 to 35% of cell cultures
in current use are infected with mycoplasmas [9]. With a
diameter of about 0.2 – 0.4 μm, mycoplasmas are small,
slow-growing bacteria that are generally unaffected by the
antibiotics used against common bacteria and fungi. They
can go undetected for long periods of time as the contam-
inated cells may grow normally and appear normal by
light microscopy. Mycoplasma contaminations can how-
ever have negative effects, ranging from inhibition of
metabolism and growth to induction of malignant trans-
formation or apoptosis [10,11]. In this study, we show
that mycoplasmas can degrade extracellular Aβ. These
results indicate that mycoplasma contaminations can
introduce an unsuspected source of variability in Aβ level
measurements in cultured cells.
Characterization of extracellular Aβ produced by APP-
transfected cells
The APP metabolites, sAPPα and Aβ, are readily detectable
in the conditioned medium of HEK293 cells stably trans-
fected with the human APP695 isoform (Figure 1B, first
lane). As expected, treatment of these cells with the selec-
tive γ-secretase inhibitor, L-685,458, prevented Aβ pro-
duction and promoted accumulation of the APP
intermediate fragments C99 and C83 (Figure 1B, second
lane).
Degradation of extracellular Aβ by mycoplasma 
contaminants
To first assess the effect of mycoplasmas on the levels of
Aβ in cell culture, medium from mycoplasma-positive
cells, detected by polymerase-mediated amplification of
mycoplasma genomic DNA (Figure 2A), was diluted 1:1
with conditioned medium from APP-transfected HEK293
cells. The resulting mixture was then incubated at 37°C
for different periods of time. Under these conditions, we
observed a robust degradation of Aβ after 1 hr of incuba-
tion, while sAPPα levels were not affected (Figure 2B,
APP processing Figure 1
APP processing. (A) Schematic representation of APP processing. APP 
undergoes two alternative endoproteolytic pathways. In the amyloidogenic 
pathway, APP is first cleaved by β-secretase (β) to enable the production 
of the membrane bound C99 fragment. C99 is then cleaved in its intram-
embranous domain by γ-secretase (γ) to release Aβ. In the non-amyloidog-
enic pathway, APP is cleaved by α-secretase (α) to generate sAPPα and 
the membrane bound C83 fragment. Immunogenic regions for the indi-
cated anti-APP antibodies are shown. (B) HEK293 cells stably transfected 
with Swedish human APP695 cDNA [16] were incubated in the absence 
(Control) or presence of γ-secretase inhibitor (L-685,458, Calbiochem, 1 
μM for 18 hrs). APP full-length (APP) and C-terminal fragments (C99 and 
C83) were analyzed by western blotting (WB) as described before [16], 
using antibodies directed against APP N-terminal domain (22C11, Chemi-
con) and APP C-terminal domain (R1, provided by Dr. P.D. Mehta, see 
Ref. [16]), respectively. Secreted sAPPα and Aβ were analyzed by WB 
using anti-APP1–17 antibody (6E10, Signet). Wild type and APP-transfected 
HEK293 cells were grown in DMEM plus 10% FBS, penicillin and strepto-
mycin in 5% CO2 at 37°C. APP-transfected HEK293 cells were selected 
and maintained in 5 μg/ml puromycin.
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Degradation of extracellular Aβ by mycoplasma contaminants Figure 2
Degradation of extracellular Aβ by mycoplasma contaminants. (A) PCR amplification of mycoplasma genomic DNA 
was performed with an internal negative control template (Control -), a positive control template of M. orale genomic DNA 
(Control +), or with medium from mycoplasma-positive HEK293 cell cultures (Mycoplasma+ Medium). Assay was carried out 
according to manufacturer's instructions (MycoSensor PCR Assay Kit, Stratagene). The changes in intensity of the internal con-
trol amplification are due to competition with the mycoplasma-specific PCR. (B) Medium from mycoplasma-positive cells was 
centrifuged at 1000 × g for 10 min to pellet the cell debris. Conditioned medium from APP-transfected HEK293 cells was 
diluted 1:1 with either fresh medium (Control DMEM), or with unfiltered (Mycoplasma+ Medium) or 0.2 μm filtered [Myco-
plasma+ Medium (Filtered)] medium from mycoplasma-positive cells. The resulting mixtures were incubated at 37°C for the 
indicated periods of time. sAPPα and Aβ were analyzed by WB, as described in Figure 1B.
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lanes 3–6). Aβ degradation did not occur when fresh
medium (Control DMEM) was mixed with Aβ-containing
medium (Figure 2B, lanes 1 and 2). Importantly, reduc-
tion of the contaminant load by a 0.2 μm filtration of the
mycoplasma-positive medium prior to incubation, signif-
icantly prevented Aβ degradation (Figure 2B, lanes 7–10).
Together these data strongly indicate that mycoplasmas
efficiently degrade Aβ during normal cell culture condi-
tions.
Mycoplasma contamination prevents Aβ accumulation in 
APP-transfected cells
In order to confirm the detrimental effect of mycoplasma
contamination on Aβ accumulation in cell culture, we
directly analyzed Aβ levels produced by mycoplasma-pos-
Mycoplasma eradication restored Aβ accumulation in APP-transfected cells Figure 3
Mycoplasma eradication restored Aβ accumulation in APP-transfected cells. (A) APP (first panel) and Aβ (second 
panel) levels in wild-type (wt-293) and APP-transfected (APP-293) HEK293 cells were analyzed by WB, as described before. 
APP-293 cells were cultured for one week in the absence (-MRA) or presence (+MRA) of Mycoplasma Removal Agent (MRA, 
MP Biomedicals, Inc). Conditioned medium of untreated and treated APP-293 cells was analyzed by PCR for the presence of 
mycoplasma genomic DNA (lower panel), as described above. Twenty-five picograms of synthetic Aβ1–40 (IBL-America) were 
loaded as a control (lane 4). (B) Determination of the mycoplasma species by restriction fragment polymorphism analysis of 
PCR products. The PCR product was digested with six different restriction endonucleases as indicated and separated on an 
agarose gel. The fragment pattern identifies the contaminant as M. hyorhinis. Briefly, a PCR reaction is performed with a mix of 
9 primers to cover a range of mycoplasma species, including major contaminants of cell cultures. The 500–520 bp PCR prod-
ucts, depending on the species, are then subjected to several digests with restriction endonucleases to differentiate between 7 
mycoplasma species, as previously described [14]. Cells were cultured without antibiotic for several days. 1 ml of supernatant 
and 1 ml of trypsinized cells were centrifuged for 10 min at 13,000 rpm and DNA was extracted using DNeasy Blood and Tis-
sue Kit (Qiagen). The PCR was carried out in 50 μl containing 0.2 mM of each deoxynucleotide, 0.2 μM of each primer 
(sequences provided in Ref. [17]), 1.5 mM MgCl2. PCR conditions were as follows, 5 min denaturation at 95°, 35 cycles of 30 
sec at 95°C, 30 sec annealing at 65°C and 1 min extension at 72°C followed by a final extension for 10 min. 5 μl of the PCR 
products were used for restriction digests in 20 μl of reaction volume for 3 hrs. The following enzymes were used: Pfl FI 
(isoschizomer of Asp I), Bam HI, Hae III, Hpa I, BstBI (isoschizomer of Sfu I) and Xba I. Fragments were analyzed on a 1.5% aga-
rose gel.
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itive APP-transfected HEK293 cells. Interestingly, no Aβ
was detected in the conditioned medium of the myco-
plasma-positive cells (Figure 3A, lane 2), while these cells
strongly overexpressed APP (Figure 3A, upper panel, lanes
1 and 2).
Mycoplasma eradication restored Aβ accumulation in 
APP-transfected cells
Successful mycoplasma decontamination can be achieved
by treatments with different antibiotics, including qui-
nolones and tetracyclines [9]. Contaminated APP-trans-
fected cells were treated for one week with the quinolone-
based antibiotic, MRA (4-oxo-quinolone-3-carboxylic
acid derivative). The antibiotic treatment successfully
eradicated the mycoplasmas (Figure 3A, lower panel), and
restored Aβ accumulation in the conditioned medium of
the APP-transfected cells (Figure 3A, middle panel). M.
hyorhinis, M. orale, M. arginini, M. fermentans, M. hominis
and Acholeplasma laidlawii represent 90–95% of the con-
taminants in mycoplasma-positive cells [12,13]. By
restriction fragment length polymorphism assay of PCR
products amplified from a region of the conserved 16S
rDNA gene in mycoplasma species [14], we determined
that the APP-transfected cells were contaminated with the
M. hyorhinis species (Figure 3B). Together these results
show that mycoplasmas degrade Aβ in cell cultures.
Discussion
Aβ peptides are degraded in cell culture systems and in
vivo by at least four peptidases from the metallopeptidase
family, neprilysin, endothelin-converting enzyme-1 and -
2, and insulin-degrading enzyme [15]. Bacteria express
numerous proteases with important biological activities,
such as degradation of tissue matrix proteins or activation
of zymogens through limited proteolysis. The vast major-
ity of the contaminations in mycoplasma-positive cells
are due to M. hyorhinis, M. orale, M. arginini, M. fermentans,
M. hominis and  Acholeplasma laidlawii [12,13]. Partial
sequencing of the M. hominis genome predicted the
expression of at least three metallopeptidases, and M. pen-
etrans, a mycoplasma species isolated from human, is pre-
dicted to express oligopeptidase O1, a metallopeptidase
from the M13 neprilysin family. Here M. hyorhinis was
identified in the contaminated APP-transfected cell lines.
It is conceivable that M. hyorhinis also expresses metal-
lopeptidases with homologies with known mammalian
metallopeptidases, which degrade Aβ but not large
secreted proteins, such as sAPPα. Contamination with
mycoplasmas would therefore provide a very efficient
peptidase-driven mechanism of Aβ clearance.
In conclusion, we show that (i) mycoplasmas from cell
culture contaminations degrade in vitro Aβ produced in
cell lines, (ii) mycoplasma-positive APP-transfected cells
do not accumulate Aβ in the conditioned medium, and
(iii) eradication of the mycoplasma contaminant (i.e. M.
hyorhinis) by treatments with a quinolone-based antibi-
otic, restored extracellular Aβ accumulation in APP-trans-
fected cells. Together these results demonstrate that
mycoplasmas may represent a significant source of varia-
bility when comparing extracellular Aβ levels between dif-
ferent cell lines. We therefore recommend assessment of
mycoplasma contamination prior to extracellular Aβ level
measurements in cultured cells.
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